Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Economics of Cancer Care
Promise of Personalized Care Hinges on Reimbursement Reform
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
The promise of big data–driven personalized healthcare mandates reform of the oncology reimbursement system, suggested Jeffery C. Ward, MD, Medical Oncologist, Swedish Cancer Institute, Edmonds, WA, in a recent commentary.
Read Article
Implications of the ACA for Cancer Care
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
Hollywood, FL—The Affordable Care Act (ACA) is in its infancy, but it is already changing oncology practice, said panelists at the 2014 National Comprehensive Cancer Network (NCCN) Conference roundtable discussion. The consequences of the ACA include the changing composition of oncology patients, the risk pool of the exchanges, new payment and reimbursement models, acquisition fever, and oncology workforce demands, the panelists said.
Read Article
ACA Heralds Modest Increase in Healthcare Utilization for Testicular Seminoma
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
San Francisco, CA—Concerns that healthcare utilization will increase dramatically once more patients are insured under the Affordable Care Act (ACA) may be overblown, based on results of a large study of Medicaid and underinsured patients with seminoma, the most common type of testicular cancer.
Read Article
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
New Orleans, LA—The efficiency of rituximab (Rituxan) and the associated cost can be improved by switching from intravenous (IV) to subcutaneous (SC) administration. Such a switch led to a substantial reduction in patient chair time and in active healthcare professional time, said Christof Wiesner, PhD, MPH, of the Market Access Department, Genentech, San Francisco, CA, at the ASH 2013 meeting.
Read Article
Genetic Test for Breast Cancer Screening Cost-Effective for Women at Intermediate Risk
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
The American Cancer Society has recommended annual magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in women who have a lifetime risk of breast cancer of approximately 25% to ?50%, as determined by models such as the Gail risk test. A new simulated clinical trial evaluated the cost-effectiveness of using 7 single-nucleotide polymorphisms (7SNPs) in combination with the Gail test to assess the cost-benefit of annual MRI screening in women at risk for breast cancer (Folse HJ, et al.
Cancer Prev Res [Phila]
. 2013;6:1328-1336).
Read Article
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—New research has confirmed that 30-day readmission for reduced-toxicity conditioning allogeneic hematopoietic-cell transplantation (allo-HCT) is linked to greater 100-day posttransplant hospital charges.
Read Article
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—More patients with diffuse large B-cell lymphoma (DLBCL) are receiving rituximab infusions in the hospital setting, incurring greater costs than those receiving infusions in the office or clinic, an examination of medical and pharmacy claims has shown.
Read Article
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—Recipients of allogeneic hematopoietic cell transplant are at high risk for financial burden, according to survey-based data collected by Nandita Khera, MD, MPH, a medical oncologist from the Blood and Marrow Transplant Program, Mayo Clinic Arizona, Phoenix, and colleagues.
Read Article
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—The use of decitabine (Dacogen) is more cost-effective than conventional induction therapy for patients aged >60 years with acute myeloid leukemia (AML), according to data from a recent economic analysis.
Read Article
Higher Copays for Imatinib Lead to Medication Nonadherence in Patients with CML
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>Patients with chronic myeloid leukemia (CML) and high out-of-pocket (OOP) costs for treating their disease have a 70% chance of discontinuing treatment and a 42% chance of nonadherence to treatment compared with patients with lesser copays. These conclusions, which were recently published online (Dusetzina SB, et al.
J Clin Oncol
.
Read Article
Page 5 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma